How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Anti-Inflammatory Analgesic and Antipyretic Drugs Market
- By Drug Type: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Acetaminophen (Paracetamol), Selective COX-2 Inhibitors, Salicylates, Combination Analgesics
- By Route of Administration: Oral, Topical, Injectable, Rectal, Transdermal
- By Indication: Rheumatoid Arthritis, Osteoarthritis, Fever Management, Postoperative Pain, Musculoskeletal Pain
- By End User: Hospitals, Clinics, Retail Pharmacies, Home Healthcare, Ambulatory Surgical Centers
- By Formulation: Tablets, Capsules, Suspensions, Creams and Gels, Suppositories
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) leads By Drug Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 305 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.186 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.194 →
Full report · locked preview
Everything inside the Anti-Inflammatory Analgesic and Antipyretic Drugs Market report
A complete, evidence-based study - 12 chapters and 128 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Drug Type 5
Route of Administration 5
Indication 5
End User 5
Formulation 5
Companies profiled
Johnson & Johnson
Pfizer Inc.
Bayer AG
Novartis AG
Sanofi S.A.
GlaxoSmithKline plc
AbbVie Inc.
Teva Pharmaceutical Industries Ltd.
Mylan N.V. (now part of Viatris)
AstraZeneca plc
Eli Lilly and Company
Bristol-Myers Squibb Company
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Johnson & Johnson
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Sanofi S.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →GlaxoSmithKline plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →AbbVie Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Teva Pharmaceutical Industries Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Mylan N.V. (now part of Viatris)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →AstraZeneca plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Eli Lilly and Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Bristol-Myers Squibb Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Sun Pharmaceutical Industries Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Dr. Reddy's Laboratories Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Zydus Cadila
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$8,751M by 2033 · 5.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)38.0
- Acetaminophen (Paracetamol)19.6
- Selective COX-2 Inhibitors15.1
- Salicylates18.8
- Combination Analgesics8.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,831M → $3,240M · 7.4%
Europe$1,276M → $1,785M · 4.3%
Asia Pacific$1,165M → $1,763M · 5.3%
Latin America$721.4M → $1,140M · 5.9%
Middle East and Africa$554.9M → $971.6M · 7.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.822026
5.822027
5.842028
5.842029
5.862030
5.882031
5.892032
5.902033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Johnson & Johnson13.4
- Pfizer Inc.24.8
- Bayer AG6.2
- Novartis AG9.8
- Sanofi S.A.10.0
- GlaxoSmithKline plc7.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Drug Type23.9%
Route of Administration12.0%
Indication15.8%
End User24.1%
Formulation24.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America36.4
- Europe20.1
- Asia Pacific19.8
- Latin America12.8
- Middle East and Africa10.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Johnson & Johnson | 73 | 76 | 84 | 87 | 89 | 92 | 84 |
| Pfizer Inc. | 89 | 70 | 81 | 90 | 86 | 82 | 83 |
| Bayer AG | 87 | 85 | 64 | 67 | 83 | 68 | 76 |
| Novartis AG | 73 | 58 | 81 | 79 | 62 | 74 | 71 |
| Sanofi S.A. | 74 | 76 | 53 | 73 | 73 | 59 | 68 |
| GlaxoSmithKline plc | 63 | 47 | 54 | 56 | 53 | 56 | 55 |
| AbbVie Inc. | 56 | 58 | 47 | 49 | 51 | 46 | 51 |
| Teva Pharmaceutical Industries Ltd. | 54 | 48 | 51 | 39 | 46 | 38 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Johnson & Johnson
- Pfizer Inc.
- Bayer AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Johnson & Johnson | ◐ | − | ◐ | ✓ | ✓ | ✓ |
| Pfizer Inc. | ✓ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Bayer AG | ◐ | ✓ | − | − | ◐ | ◐ |
| Novartis AG | ◐ | ◐ | ✓ | ✓ | − | ✓ |
| Sanofi S.A. | ◐ | ◐ | − | ◐ | ◐ | ◐ |
| GlaxoSmithKline plc | − | ◐ | − | ◐ | ◐ | − |
| AbbVie Inc. | ◐ | ◐ | − | ◐ | − | ◐ |
| Teva Pharmaceutical Industries Ltd. | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Johnson & Johnson84
2Pfizer Inc.83
3Bayer AG76
4Novartis AG71
5Sanofi S.A.68
6GlaxoSmithKline plc55
7AbbVie Inc.51
8Teva Pharmaceutical Industries Ltd.46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Johnson & JohnsonPfizer Inc.
Challenger3
Strong scale, closing on the leaders.
Bayer AGNovartis AGSanofi S.A.
Niche3
Specialists in a single segment or region.
GlaxoSmithKline plcAbbVie Inc.Teva Pharmaceutical Industries Ltd.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Drug Type in North America, then scale across Anti-Inflammatory Analgesic and Antipyretic Drugs Market — a $398M beachhead inside a $5.43B market.
Beachhead (SOM)$398Mobtainable near-term
Serviceable (SAM)$2.16Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Best fit — highest urgency & budget in Drug Type.
Economic buyer78 fit
Acetaminophen (Paracetamol)
Strong fit — clear ROI and a fast path to value.
End user67 fit
Selective COX-2 Inhibitors
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Route of Administration & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Indication
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel28%
Digital / self-serve19%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Drug Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Anti-Inflammatory Analgesic and Antipyretic Drugs Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified20%
Evaluation12%
Closed-won6%
$8.6KCAC
$41KLTV
4.7:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Anti-Inflammatory Analgesic and Antipyretic Drugs Market is a resilient opportunity — $4.37B by 2033, compounding at 4.4%.
TAM · 2025$3.09Btoday
TAM · 2033$4.37Bforecast
CAGR4.4%2027–2033
Cumulative$33.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.37BTotal addressable market
SAM$1.77BServiceable available market
SOM$288MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.4% CAGR
Demand compounds through 2033, outpacing GDP across Drug Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.37BLarge & growingTAM by 2033 at 4.4% CAGR
$1.77BServiceable nowreachable with today’s model
$288MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.41BBear2.9% CAGR
$4.37BBase4.4% CAGR
$5.59BBull5.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Route of Administration optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Anti-Inflammatory Analgesic and Antipyretic Drugs Market — a $7.16B market by 2033. Plan: grow share from 8.2% to 13.6%.
Market size · 2033$7.16Btotal addressable
Market CAGR10.7%2027–2033
Target share13.6%from 8.2% today
Revenue ambition$974Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.2% | 13.6% | On track |
| Revenue | $597M | $974M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 31.1% | 43.5% | Behind |
| Customer retention | 88.6% | 94.4% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Drug Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Route of Administration capability
A defensible second engine — invest in Route of Administration to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Route of Administration
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $141M capacity & capability investment
- Greenlight bolt-on M&A in Route of Administration
- Authorise North America expansion plan
- Fund R&D program for Drug Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskAhead
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Anti-Inflammatory Analgesic and Antipyretic Drugs Market conversation — a $2.57B market you can size, segment and defend in minutes.
Market size · 2033$2.57Btotal opportunity
Growth5.4%CAGR to 2033
Addressable buyers1,742+accounts in scope
Typical ROI4.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Type
Goal Grow share in Drug Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.6×return on cost, year one
< 3 mopayback period
$98K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Johnson & JohnsonPfizer Inc.Bayer AGNovartis AGSanofi S.A.GlaxoSmithKline plcAbbVie Inc.Teva Pharmaceutical Industries Ltd.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Anti-Inflammatory Analgesic and Antipyretic Drugs Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Anti-Inflammatory Analgesic and Antipyretic Drugs Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Anti-Infective Therapy Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportHemodialysis and Peritoneal Dialysis Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportAnti-infectives Medicine Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportHead Band Ophthalmoscopes Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportAnti-infective Ophthalmic Preparation Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportHAIs Control Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportAnti-infective Drugs for Animals Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportGel Imaging Documentation Market
Market size, share, segmentation and regional forecast.
$866M market · 2025 base year
View reportAnti-infectious Disease Drugs Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportFoot Orthotic Insoles Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportAnti-Infection Advanced Wound Dressings Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportElectrodes for Medical Devices Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.